Nano Dimension Ltd. appointed Nadav Kidron as a Class II independent director effective August 16, 2026. Mr. Kidron currently serves as President and CEO of Oramed Pharmaceuticals Inc. and will also serve on the Audit and Compensation Committees. Additionally, the company disclosed that the 30-day exclusivity period under its non-binding term sheet with Infinite Epigenetics, Inc. expired on July 15, 2026, and no definitive agreement has been reached. Nano Dimension Ltd. operates in the advanced manufacturing industry, specializing in industrial 3D printing technologies.

Nano Dimension Ltd. entered into a settlement agreement with Murchinson Ltd. on July 17, 2026, resulting in a change in control of the company. The agreement includes the resignation of CEO David Stehlin and directors Robert Pons, David Stehlin, Dr. Joshua Rosensweig, and Andrew Sriubas, and the appointment of Pinchos (Paul) Fruchthandler, Moshe Rozenbaum, and Eliezer Eli Tarlow to the Board. Additionally, the previously scheduled July 31, 2026, Extraordinary General Meeting of Shareholders was cancelled. Nano Dimension Ltd. operates in the digital manufacturing technologies industry, providing advanced manufacturing solutions for defense, aerospace, automotive, electronics, and medical device segments.

On July 17, 2026, Nano Dimension announced an agreement to terminate the lease for its corporate headquarters effective December 31, 2026. The lease, originally entered into by MarkForged, Inc. in 2021 and set to expire in 2031, will be terminated in exchange for a $13 million payment. This action is expected to eliminate $38 million in cumulative future lease costs, resulting in approximately $25 million in cumulative net cash savings. The company operates in the advanced digital manufacturing technology industry, serving defense, aerospace, automotive, electronics, and medical device segments.

On June 16, 2026, Nano Dimension Ltd. issued a press release providing additional information regarding a proposed business combination with Infinite Epigenetics, Inc. The company has filed a preliminary proxy statement for an extraordinary general meeting of shareholders to consider a non-binding advisory resolution on the continuation of its strategic alternatives review process. If a definitive agreement is executed, Nano expects to file a registration statement on Form S-4 containing a proxy statement and prospectus. Nano Dimension operates in the additive manufacturing industry, specializing in 3D printing technology.

On June 15, 2026, Nano Dimension Ltd. entered into a non-binding term sheet to acquire Infinite Epigenetics, Inc. in an all-stock transaction. The valuation of Infinite is set at $890 million, less a premium based on Nano's net cash. Nano's valuation for the exchange ratio will include 100% of its net cash plus a 20% premium, an estimated $20 million for Essemtec, and other remaining assets. The combined company's board will consist of seven members, with Infinite designating four or five members depending on their final ownership percentage. Nano may reimburse Infinite up to $3 million in expenses if a definitive agreement is not reached by the next Extraordinary General Meeting. The agreement includes a 30-day exclusivity period. Nano Dimension operates in the additive manufacturing and electronics industry, providing 3D printing solutions.